Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| 2R01AI047040-11A2 | U.S. NIH Grant/Contract | View source | |
| R56 Bridge R01AI4704011A1 | Other Grant/Funding Number | [NIH American Recovery and Reinvestment Act (ARRA) of 2009] | |
| 5K12HD043494-09 | U.S. NIH Grant/Contract | View source | |
| R01AI047040 | U.S. NIH Grant/Contract | View source | |
| R01AI054843 | U.S. NIH Grant/Contract | View source | |
| 950 | Other Identifier | Duke |
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institutes of Health (NIH) | NIH |
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | NIH |
Not provided
Not provided
Not provided
Not provided
The study purpose is to determine if cultured thymus tissue implantation (CTTI) (previously described as transplantation) with tailored immunosuppression based on the recipient's pre-implantation T cell population is a safe and effective treatment for complete DiGeorge anomaly. This study will also evaluate whether cultured thymus tissue implantation and parathyroid transplantation with immunosuppression is a safe and effective treatment for complete DiGeorge anomaly and hypoparathyroidism.
Complete DiGeorge anomaly is a congenital disorder characterized by athymia. Without successful treatment, children remain immunodeficient and usually die by age 2 years. In infants with complete DiGeorge anomaly and no T cells, cultured thymus tissue implantation (CTTI) without immunosuppression resulted in diverse T cell development and good T cell function. Some infants with no thymus have some T cells that presumably developed extrathymically; these T cells can reject a thymus graft.
The purpose of this study is to tailor immunosuppression use for complete DiGeorge anomaly subjects who have some T cells and different T cell function levels. This protocol includes tailored immunosuppression regimens to allow subjects with different T cell function levels to be suppressed adequately.
Patients with complete DiGeorge often have hypoparathyroidism, a life threatening condition. Successful CTTI does not result in improvement of the hypoparathyroidism. The patients must go to the clinic for frequent calcium levels and to the hospital for calcium infusions. These infants are at risk for seizures from low calcium. This study had a parental parathyroid transplant arm for subjects with hypoparathyroidism who require calcium replacement.
Whether or not a subject was enrolled in the parathyroid arm, the immunosuppression regimen the subject received was dependent on the immune findings as stated in the clinical protocol.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Cultured Thymus Tissue Implantation (CTTI) w/immunosuppression | Experimental | Patients with complete DiGeorge Anomaly (cDGA) undergo cultured thymus tissue implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. |
|
| CTTI with Parathyroid Transplantation w/immunosuppression | Experimental | Patients with complete DiGeorge Anomaly (cDGA) undergoes cultured thymus tissue thymus implantation (previously described as transplantation) with tailored immunosuppression based on the subject's pre-implantation T cell numbers and function. If the patient has hypoparathyroidism, and is eligible, the patient may also receive a parathyroid transplant. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Cultured Thymus Tissue for Implantation (CTTI) | Biological | Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of implantation and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol. |
| Measure | Description | Time Frame |
|---|---|---|
| Survival at 1 Year Post-CTTI | Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time. | 1 year post-CTTI |
| Measure | Description | Time Frame |
|---|---|---|
| Survival at 2 Years Post-CTTI | Survival at 2 years post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time. | 2 years post-CTTI |
| Immune Reconstitution Efficacy - Total CD3 T Cells |
Not provided
Thymus Transplantation Inclusion:
Atypical DiGeorge:
Typical DiGeorge:
Parathyroid Transplantation Additional Inclusion:
Thymus Transplantation Exclusion:
Parathyroid Donor Inclusion:
Parathyroid Donor Exclusion:
Mother of DiGeorge Inclusion:
• Provides consent to use blood/buccal sample. No exclusions except unwillingness to consent; or, provide blood/buccal sample.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| M. Louise Markert, MD, PhD | Duke University Medical Center, Pediatrics, Allergy & Immunology | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Medical Center | Durham | North Carolina | 27710 | United States |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 17284531 | Background | Markert ML, Devlin BH, Alexieff MJ, Li J, McCarthy EA, Gupton SE, Chinn IK, Hale LP, Kepler TB, He M, Sarzotti M, Skinner MA, Rice HE, Hoehner JC. Review of 54 patients with complete DiGeorge anomaly enrolled in protocols for thymus transplantation: outcome of 44 consecutive transplants. Blood. 2007 May 15;109(10):4539-47. doi: 10.1182/blood-2006-10-048652. Epub 2007 Feb 6. | |
| 15100156 | Background | Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, Sedlak DA, Sempowski GD, Hale LP, Rice HE, Mahaffey SM, Skinner MA. Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome. Blood. 2004 Oct 15;104(8):2574-81. doi: 10.1182/blood-2003-08-2984. Epub 2004 Apr 20. |
Not provided
Not provided
The goal of this study is survival of subjects after cultured thymus tissue implantation (CTTI) regardless of the immunosuppressive regimen or of parathyroid co-transplantation.
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Cultured Thymus Tissue Implantation w/ Immunosuppression | Participants enrolled in cultured thymus tissue implantation (CTTI) with immunosuppression were given immunosuppression based on results of flow cytometry without consideration of whether a parathyroid transplant would be given. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. No specific dose of cultured thymus tissue was assigned. The dose was the number of grams of cultured thymus tissue divided by the weight of the recipient in kg or per square meter of body surface area of the participant. There was one administration of cultured thymus tissue. The dosage form was cultured thymus tissue. |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Cultured Thymus Tissue Implantation and Parental Parathyroid Transplantation | Other | For subjects w/ hypoparathyroidism, the subject may receive CTTI and parathyroid transplant. For parathyroid transplant, parental parathyroid donors are screened. Parathyroid is harvested from the parent who shares the most Human Leukocyte Antigens (HLA) alleles with the thymus donor. Parathyroid gland is minced and placed in quadriceps muscle; there is no dose. Parathyroid donors are monitored as outpatients until recipients' discharge. Recipients' calcium and PTH levels are monitored indefinitely. Potential thymus recipient subjects are screened for eligibility. Thymus donor (unrelated donor), and thymus donor's birth mother are screened for safety. CTTI is done under general anesthesia in the operating room. Cultured thymus tissue is implanted into the subject's quadriceps. Two to three months post CTTI, if medically stable, the subject undergoes allograft biopsy. At the time of CTTI and biopsy, a skin biopsy is done. Immunosuppression is weaned as per protocol. |
|
|
| Blood Draw | Procedure | Birth mothers of Thymus Recipients are asked to participate in the study and undergo phlebotomy to allow testing of T cell identity in the Complete DiGeorge subjects. If blood is not obtainable then a buccal swab may be done. |
|
|
| Rabbit anti-thymocyte globulin | Drug | Three doses of 2 mg/kg IV (through a central venous catheter) prior to CTTI. Each dose of Rabbit anti-thymocyte globulin (RATGAM) is given over 12 hours. RATGAM is usually given on days-5, -4, and -3 prior to CTTI or CTTI and parathyroid transplantation. Medications (diphenhydramine, steroids, and acetaminophen) are given with rabbit anti-thymocyte globulin. |
|
|
| Cyclosporine | Drug | In addition to RATGAM, subjects with typical cDGA with PHA responses >50,000 cpm, or atypical cDGA with PHA response <75,000cpm (when not on immunosuppression) or <40,000 cpm to PHA while on immunosuppression, are started on cyclosporine (Csa) as soon as cDGA is diagnosed. Csa is continued with target trough levels of 180 to 220 ng/ml. If subject cannot tolerate Csa, Csa may be changed to tacrolimus (FK506) with target trough level 7 to 10 ng/ml. When trough levels are outside of range, dosing is modified appropriately. Csa may be given every 8 to 12 hours enterally or IV before and after CTTI. The Csa dose is dependent on T cell numbers and the target Csa trough levels. Csa is weaned as per protocol. |
|
|
| Tacrolimus | Drug | If unable to tolerate cyclosporine, then tacrolimus is given. Tacrolimus may be given every 8 to 12 hours enterally or IV before and after the CTTI transplant. Tacrolimus dose is dependent on the T cell numbers and the target tacrolimus trough levels. Tacrolimus is weaned as per protocol. |
|
|
| Methylprednisolone or Prednisolone | Drug | Steroids IV or enterally may be given before and after CTTI or CTTI and parathyroid transplantation. Administration and dosage depends on T cell numbers and symptoms. Pre-transplant steroids may be used when pre-transplant T cells >4,000cumm. Steroids are weaned as per protocol. |
|
|
| Daclizumab | Drug | In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Daclizumab 1 mg/kg single dose IV may be given depending on T cell counts. Administration of Daclizumab depends on T cell numbers and T cell activation. A single dose may be given after the administration of rabbit anti-thymocyte globulin and before CTTI. If Daclizumab is not given before CTTI, and, depending on the T cell numbers and T cell activation, a single dose of Daclizumab may be given 3-5 days after CTTI. |
|
|
| Mycophenolate mofetil | Drug | In addition, subjects with Atypical DiGeorge with PHA responses >75,000cpm while on no immunosuppression or PHA responses >40,000cpm while on immunosuppression, Mycophenolate mofetil 15 mg/kg/dose every 8 hours IV or enterally may be given depending on T cell counts. Mycophenolate mofetil may be given if the T cell count remains elevated 5 days after CTTI. If MMF is given, the dose is 15 mg/kg IV. MMF may be stopped at 35 days after CTTI or continued for up to six months after CTTI. |
|
|
The development of total CD3 T cells at one year as measured using flow cytometry |
| 1 year post-CTTI |
| Immune Reconstitution Efficacy - Total CD4 T Cells | The development of total CD4 T cells at one year as measured using flow cytometry | 1 year post-CTTI |
| Immune Reconstitution Efficacy - Total CD8 T Cells | The development of total CD8 T cells at one year as measured using flow cytometry | 1 year post-CTTI |
| Immune Reconstitution Efficacy - Naive CD4 T Cells | The development of total naive CD4 T cells at one year as measured using flow cytometry | 1 year post-CTTI |
| Immune Reconstitution Efficacy - Naive CD8 T Cells | The development of total naive CD8 T cells at one year as measured using flow cytometry | 1 year post-CTTI |
| Immune Reconstitution Efficacy - Response to Mitogens | Measurement of the T cell proliferative response to the mitogen phytohemagglutin (PHA). | 1 year post-CTTI |
| Thymus Allograft Biopsy | Evidence, on biopsy of the thymus tissue implanted in muscle, that shows the development of new T cells. | 2 to 3 months post-CTTI |
| Background | Markert ML and Devlin BH. Thymic reconstitution (in Rich RR, Shearer WT, Fleischer T, Schroeder HW, Weyand CM, Frew A, eds., Clinical Immunology 3rd edn., Elsevier, Edinburgh) p 1253-1262, 2008. |
| 18333898 | Background | Selim MA, Markert ML, Burchette JL, Herman CM, Turner JW. The cutaneous manifestations of atypical complete DiGeorge syndrome: a histopathologic and immunohistochemical study. J Cutan Pathol. 2008 Apr;35(4):380-5. doi: 10.1111/j.1600-0560.2007.00816.x. |
| 18155964 | Background | Chinn IK, Devlin BH, Li YJ, Markert ML. Long-term tolerance to allogeneic thymus transplants in complete DiGeorge anomaly. Clin Immunol. 2008 Mar;126(3):277-81. doi: 10.1016/j.clim.2007.11.009. Epub 2007 Dec 26. |
| 15100681 | Background | Markert ML, Alexieff MJ, Li J, Sarzotti M, Ozaki DA, Devlin BH, Sempowski GD, Rhein ME, Szabolcs P, Hale LP, Buckley RH, Coyne KE, Rice HE, Mahaffey SM, Skinner MA. Complete DiGeorge syndrome: development of rash, lymphadenopathy, and oligoclonal T cells in 5 cases. J Allergy Clin Immunol. 2004 Apr;113(4):734-41. doi: 10.1016/j.jaci.2004.01.766. |
| 12702512 | Background | Markert ML, Sarzotti M, Ozaki DA, Sempowski GD, Rhein ME, Hale LP, Le Deist F, Alexieff MJ, Li J, Hauser ER, Haynes BF, Rice HE, Skinner MA, Mahaffey SM, Jaggers J, Stein LD, Mill MR. Thymus transplantation in complete DiGeorge syndrome: immunologic and safety evaluations in 12 patients. Blood. 2003 Aug 1;102(3):1121-30. doi: 10.1182/blood-2002-08-2545. Epub 2003 Apr 17. |
| 21565561 | Background | Li B, Li J, Devlin BH, Markert ML. Thymic microenvironment reconstitution after postnatal human thymus transplantation. Clin Immunol. 2011 Sep;140(3):244-59. doi: 10.1016/j.clim.2011.04.004. Epub 2011 Apr 16. |
| 20832849 | Background | Chinn IK, Olson JA, Skinner MA, McCarthy EA, Gupton SE, Chen DF, Bonilla FA, Roberts RL, Kanariou MG, Devlin BH, Markert ML. Mechanisms of tolerance to parental parathyroid tissue when combined with human allogeneic thymus transplantation. J Allergy Clin Immunol. 2010 Oct;126(4):814-820.e8. doi: 10.1016/j.jaci.2010.07.016. Epub 2010 Sep 15. |
| 20236866 | Result | Markert ML, Devlin BH, McCarthy EA. Thymus transplantation. Clin Immunol. 2010 May;135(2):236-46. doi: 10.1016/j.clim.2010.02.007. Epub 2010 Mar 16. |
| 18424759 | Result | Markert ML, Li J, Devlin BH, Hoehner JC, Rice HE, Skinner MA, Li YJ, Hale LP. Use of allograft biopsies to assess thymopoiesis after thymus transplantation. J Immunol. 2008 May 1;180(9):6354-64. doi: 10.4049/jimmunol.180.9.6354. |
| 18035553 | Result | Hudson LL, Louise Markert M, Devlin BH, Haynes BF, Sempowski GD. Human T cell reconstitution in DiGeorge syndrome and HIV-1 infection. Semin Immunol. 2007 Oct;19(5):297-309. doi: 10.1016/j.smim.2007.10.002. Epub 2007 Nov 26. |
| 18557726 | Result | Markert ML, Devlin BH, Chinn IK, McCarthy EA, Li YJ. Factors affecting success of thymus transplantation for complete DiGeorge anomaly. Am J Transplant. 2008 Aug;8(8):1729-36. doi: 10.1111/j.1600-6143.2008.02301.x. Epub 2008 Jun 28. |
| Result | Markert ML, Devlin BH, McCarthy EA, Chinn IK, Hale LP. Thymus Transplantation in Thymus Gland Pathology: Clinical, Diagnostic, and Therapeutic Features. Eds Lavinin C, Moran CA, Morandi U, Schoenhuber R. Springer-Verlag Italia, Milan, 2008, pp 255-267. |
| 19066739 | Result | Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009;44(1-3):61-70. doi: 10.1007/s12026-008-8082-5. |
| 23607606 | Result | Chinn IK, Milner JD, Scheinberg P, Douek DC, Markert ML. Thymus transplantation restores the repertoires of forkhead box protein 3 (FoxP3)+ and FoxP3- T cells in complete DiGeorge anomaly. Clin Exp Immunol. 2013 Jul;173(1):140-9. doi: 10.1111/cei.12088. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only.
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Cultured Thymus Tissue Implantation With Immunosuppression | Participants enrolled into cultured thymus tissue for implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject's pre-implantation T cell number and function. |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| |||||||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | days |
| ||||||||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| |||||||||||||||||||||||
| Race/Ethnicity, Customized | Count of Participants | Participants |
| |||||||||||||||||||||||
| Region of Enrollment | Count of Participants | Participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | ||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Survival at 1 Year Post-CTTI | Survival at 1 year post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time. | The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Number | 95% Confidence Interval | % of participants who survive to 1 year | 1 year post-CTTI |
|
|
| |||||||||||||||||||||||||
| Secondary | Survival at 2 Years Post-CTTI | Survival at 2 years post cultured thymus tissue implantation was assessed using the Kaplan Meier Estimated Survival. This mathematical function estimates the survival for a certain length of time. | The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Number | 95% Confidence Interval | % of participants who survive to 2 years | 2 years post-CTTI |
|
| ||||||||||||||||||||||||||
| Secondary | Immune Reconstitution Efficacy - Total CD3 T Cells | The development of total CD3 T cells at one year as measured using flow cytometry | Data were only included for the 1 year time point if a CD3 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Median | Full Range | cells/mm3 | 1 year post-CTTI |
|
| ||||||||||||||||||||||||||
| Secondary | Immune Reconstitution Efficacy - Total CD4 T Cells | The development of total CD4 T cells at one year as measured using flow cytometry | Data were only included for the 1 year time point if a CD4 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Median | Full Range | cells/mm3 | 1 year post-CTTI |
|
| ||||||||||||||||||||||||||
| Secondary | Immune Reconstitution Efficacy - Total CD8 T Cells | The development of total CD8 T cells at one year as measured using flow cytometry | Data were only included for the 1 year time point if a CD8 T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Median | Full Range | cells/mm3 | 1 year post-CTTI |
|
| ||||||||||||||||||||||||||
| Secondary | Immune Reconstitution Efficacy - Naive CD4 T Cells | The development of total naive CD4 T cells at one year as measured using flow cytometry | Data were only included for the 1 year time point if a T cell count was performed in relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Median | Full Range | cells/mm3 | 1 year post-CTTI |
|
| ||||||||||||||||||||||||||
| Secondary | Immune Reconstitution Efficacy - Naive CD8 T Cells | The development of total naive CD8 T cells at one year as measured using flow cytometry | Data were only included for the 1 year time point if a T cell count was performed in the relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Median | Full Range | cells/mm3 | 1 year post-CTTI |
|
| ||||||||||||||||||||||||||
| Secondary | Immune Reconstitution Efficacy - Response to Mitogens | Measurement of the T cell proliferative response to the mitogen phytohemagglutin (PHA). | Data were only included for the 1 year time point if a testing was performed in the relevant time period. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Median | Full Range | counts per minute (cpm) | 1 year post-CTTI |
|
| ||||||||||||||||||||||||||
| Secondary | Thymus Allograft Biopsy | Evidence, on biopsy of the thymus tissue implanted in muscle, that shows the development of new T cells. | Data were only included if the participant had a biopsy of the thymus tissue implanted. The study was designed to assess survival, without regard to the immune suppression used. No participants were enrolled into Arm 2. No subjects received a parathyroid transplant. Therefore, results are reported for Arm 1 only. | Posted | Count of Participants | Participants | 2 to 3 months post-CTTI |
|
|
2 years post-CTTI
Participants enrolled into Cultured Thymus Tissue for Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject's pre-implantation T cell numbers and function. All adverse events are reported below.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Cultured Thymus Tissue Implantation With Immunosuppression | Participants enrolled into Cultured Thymus Tissue Implantation (previously described as transplantation) with immunosuppression were given immunosuppression based on the subject's pre-implantation T cell numbers and function. All adverse events were combined for this analysis regardless of the immunosuppression used. | 4 | 14 | 13 | 14 | 14 | 14 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Device related infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cytokine release syndrome | Immune system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Tachypnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cytomegalovirus infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Respiratory failure | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypocalcaemic seizure | Nervous system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Disseminated intravascular coagulation | Blood and lymphatic system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Haemolysis | Blood and lymphatic system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Enteritis | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pancreatitis | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Systemic immune activation | Immune system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cystitis escherichia | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cystitis klebsiella | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Enterobacter bacteraemia | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Enterococcal bacteraemia | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Gastroenteritis rotavirus | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Lower respiratory tract infection fungal | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pneumonia haemophilus | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pneumonia moraxella | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Respiratory tract infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Staphylococcal skin infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Wound complication | Injury, poisoning and procedural complications | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood bicarbonate decreased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Feeding intolerance | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cerebral atrophy | Nervous system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Renal failure | Renal and urinary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Chylothorax | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Granuloma skin | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Thrombosis | Vascular disorders | MedDRA 19.1 | Non-systematic Assessment |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Hypertension | Vascular disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypomagnesaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cytokine release syndrome | Immune system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypothyroidism | Endocrine disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Urinary tract infection bacterial | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Anaemia | Blood and lymphatic system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pyrexia | General disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Alanine aminotransferase increased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Tachypnoea | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Rash | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Sinus bradycardia | Cardiac disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Occult blood positive | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Thrombocytopenia | Blood and lymphatic system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Sinus tachycardia | Cardiac disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Constipation | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Clostridium difficile colitis | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Ear infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Fungal skin infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Urinary tract infection enterococcal | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Aspartate aminotransferase increased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cough | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Eye infection bacterial | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood alkaline phosphatase increased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Neutropenia | Blood and lymphatic system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Diarrhoea | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Gastrooesophageal reflux disease | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Ileus | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Rhinitis | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Stoma site hypergranulation | Injury, poisoning and procedural complications | MedDRA 19.1 | Non-systematic Assessment |
| |
| Wound dehiscence | Injury, poisoning and procedural complications | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood bicarbonate decreased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood chloride decreased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood creatinine increased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood urea increased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hyperglycaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypocalcaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hyponatraemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Seizure | Nervous system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Proteinuria | Renal and urinary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypoxia | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Dermatitis diaper | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Erythema | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Seborrhoeic dermatitis | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypersensitivity | Immune system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Oral candidiasis | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Urinary tract infection pseudomonal | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Allergic transfusion reaction | Injury, poisoning and procedural complications | MedDRA 19.1 | Non-systematic Assessment |
| |
| Skin disorder | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hydrocele | Congenital, familial and genetic disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Abdominal distension | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Diarrhoea haemorrhagic | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Gastric haemorrhage | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Haematochezia | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pneumatosis intestinalis | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Rectal prolapse | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Vomiting | Gastrointestinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Injection site reaction | General disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cholestasis | Hepatobiliary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hepatomegaly | Hepatobiliary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hyperbilirubinaemia | Hepatobiliary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Cystitis klebsiella | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Eye infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Gastroenteritis adenovirus | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Gastrointestinal bacterial infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Otitis media | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Otitis media acute | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pneumonia moraxella | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Staphylococcal bacteraemia | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Staphylococcal skin infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Stoma site infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Urinary tract infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Urinary tract infection staphylococcal | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Viral diarrhoea | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Viral upper respiratory tract infection | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Wound infection staphylococcal | Infections and infestations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Transfusion reaction | Injury, poisoning and procedural complications | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood immunoglobulin E increased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Blood triglycerides increased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Protein total decreased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Red blood cell morphology abnormal | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Weight decreased | Investigations | MedDRA 19.1 | Non-systematic Assessment |
| |
| Disaccharidase deficiency | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Feeding intolerance | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Fluid retention | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hyperkalaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypermagnesaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypoalbuminaemia | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Metabolic alkalosis | Metabolism and nutrition disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Hypotonia | Nervous system disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Nephrocalcinosis | Renal and urinary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pyelocaliectasis | Renal and urinary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Renal failure | Renal and urinary disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Bilateral breast buds | Reproductive system and breast disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Ovarian cyst | Reproductive system and breast disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Pulmonary oedema | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Wheezing | Respiratory, thoracic and mediastinal disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Alopecia | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Dermatitis atopic | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Exfoliative rash | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Palmar-plantar erythrodysaesthesia syndrome | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Rash maculo-papular | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Rash papular | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Rash pruritic | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Skin ulcer | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Urticaria | Skin and subcutaneous tissue disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Lymphorrhoea | Vascular disorders | MedDRA 19.1 | Non-systematic Assessment |
| |
| Thrombosis | Vascular disorders | MedDRA 19.1 | Non-systematic Assessment |
|
Not provided
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| M. Louise Markert, MD, PhD Professor of Pediatrics and Immunology | Duke University Medical Center | 919-684-6263 | marke001@mc.duke.edu |
| ID | Term |
|---|---|
| D004062 | DiGeorge Syndrome |
| C536288 | Thymic aplasia |
| D006996 | Hypocalcemia |
| D007011 | Hypoparathyroidism |
| D007153 | Immunologic Deficiency Syndromes |
| ID | Term |
|---|---|
| D058165 | 22q11 Deletion Syndrome |
| D019465 | Craniofacial Abnormalities |
| D009139 | Musculoskeletal Abnormalities |
| D009140 | Musculoskeletal Diseases |
| D006330 | Heart Defects, Congenital |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D044148 | Lymphatic Abnormalities |
| D008206 | Lymphatic Diseases |
| D006425 | Hemic and Lymphatic Diseases |
| D000015 | Abnormalities, Multiple |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
| D025063 | Chromosome Disorders |
| D030342 | Genetic Diseases, Inborn |
| D010279 | Parathyroid Diseases |
| D004700 | Endocrine System Diseases |
| D002128 | Calcium Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
| D014883 | Water-Electrolyte Imbalance |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004343 | Drug Implants |
| D013949 | Thymus Extracts |
| D001800 | Blood Specimen Collection |
| D018962 | Phlebotomy |
| D000961 | Antilymphocyte Serum |
| C512542 | thymoglobulin |
| D016572 | Cyclosporine |
| D003524 | Cyclosporins |
| D016559 | Tacrolimus |
| D008775 | Methylprednisolone |
| D011239 | Prednisolone |
| D013256 | Steroids |
| D000077561 | Daclizumab |
| D009173 | Mycophenolic Acid |
| ID | Term |
|---|---|
| D003692 | Delayed-Action Preparations |
| D004304 | Dosage Forms |
| D004364 | Pharmaceutical Preparations |
| D014020 | Tissue Extracts |
| D045424 | Complex Mixtures |
| D013048 | Specimen Handling |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D011677 | Punctures |
| D013514 | Surgical Procedures, Operative |
| D008919 | Investigative Techniques |
| D013812 | Therapeutics |
| D007106 | Immune Sera |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D001688 | Biological Products |
| D010456 | Peptides, Cyclic |
| D047028 | Macrocyclic Compounds |
| D011083 | Polycyclic Compounds |
| D010455 | Peptides |
| D018942 | Macrolides |
| D007783 | Lactones |
| D009930 | Organic Chemicals |
| D011246 | Pregnadienetriols |
| D011245 | Pregnadienes |
| D011278 | Pregnanes |
| D000072473 | Fused-Ring Compounds |
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D002208 | Caproates |
| D000144 | Acids, Acyclic |
| D002264 | Carboxylic Acids |
| D005227 | Fatty Acids |
| D008055 | Lipids |
Not provided
Not provided
| American Indian or Alaska Native |
|
| More than One Race (Caucasian/Asian) |
|
|
|
|
|
|
|
|
|